Literature DB >> 15958592

Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70.

Ali Chahlavi1, Patricia Rayman, Amy L Richmond, Kaushik Biswas, Renliang Zhang, Michael Vogelbaum, Charles Tannenbaum, Gene Barnett, James H Finke.   

Abstract

Here we report that glioblastoma multiforme (GBM) mediates immunosuppression by promoting T-cell death via tumor-associated CD70 and gangliosides that act through receptor-dependent and receptor-independent pathways, respectively. GBM lines cocultured with T cells induced lymphocyte death. The GBM lines were characterized for their expression of CD70, Fas ligand (FasL), and tumor necrosis factor-alpha (TNF-alpha), and the possible participation of those molecules in T-cell killing was assessed by doing GBM/T cell cocultures in the presence of anti-CD70 antibodies, Fas fusion proteins, or anti-TNF-alpha antibodies. CD70 but not TNF-alpha or FasL is responsible for initiating T-cell death via the receptor-dependent pathway. Of the four GBM cell lines that induced T-cell death, three highly expressed CD70. Two nonapoptogenic GBM lines (CCF3 and U138), on the other hand, had only minimally detectable CD70 expression. Blocking experiments with the anti-CD70 antibody confirmed that elevated CD70 levels were involved in the apoptogenicity of the three GBM lines expressing that molecule. Gangliosides were found to participate in the induction of T-cell apoptosis, because the glucosylceramide synthase inhibitor (PPPP) significantly reduced the abilities of all four apoptogenic lines to kill the lymphocytes. High-performance liquid chromatography (HPLC) and mass spectroscopy revealed that GM2, GM2-like gangliosides, and GD1a were synthesized in abundance by all four apoptogenic GBM lines but not by the two GBMs lacking activity. Furthermore, gangliosides isolated from GBM lines as well as HPLC fractions containing GM2 and GD1a were directly apoptogenic for T cells. Our results indicate that CD70 and gangliosides are both products synthesized by GBMs that may be key mediators of T-cell apoptosis and likely contribute to the T-cell dysfunction observed within the tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958592     DOI: 10.1158/0008-5472.CAN-04-4395

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

Review 2.  Immunosuppressive mechanisms in glioblastoma.

Authors:  Edjah K Nduom; Michael Weller; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

3.  TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma.

Authors:  Z-Z Yang; D M Grote; B Xiu; S C Ziesmer; T L Price-Troska; L S Hodge; D M Yates; A J Novak; S M Ansell
Journal:  Leukemia       Date:  2014-02-26       Impact factor: 11.528

4.  Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.

Authors:  Drew Pratt; Stefania Pittaluga; Maryknoll Palisoc; Patricia Fetsch; Liqiang Xi; Mark Raffeld; Mark R Gilbert; Martha Quezado
Journal:  J Neuropathol Exp Neurol       Date:  2017-08-01       Impact factor: 3.685

5.  Elevated histone H3 acetylation and loss of the Sp1-HDAC1 complex de-repress the GM2-synthase gene in renal cell carcinoma.

Authors:  Avisek Banerjee; Barun Mahata; Arjun Dhir; Tapan Kumar Mandal; Kaushik Biswas
Journal:  J Biol Chem       Date:  2018-11-21       Impact factor: 5.157

Review 6.  Immunotherapy of Primary Brain Tumors: Facts and Hopes.

Authors:  Robin A Buerki; Zinal S Chheda; Hideho Okada
Journal:  Clin Cancer Res       Date:  2018-06-05       Impact factor: 12.531

7.  CD70, a novel target of CAR T-cell therapy for gliomas.

Authors:  Linchun Jin; Haitao Ge; Yu Long; Changlin Yang; Yifan Emily Chang; Luyan Mu; Elias J Sayour; Gabriel De Leon; Qiong J Wang; James C Yang; Paul S Kubilis; Hongbo Bao; Songsong Xia; Dunyue Lu; Yingjun Kong; Li Hu; Yujiao Shang; Chencheng Jiang; Jing Nie; Shimin Li; Yunhe Gu; Jiahang Sun; Duane A Mitchell; Zhiguo Lin; Jianping Huang
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

8.  Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages.

Authors:  Orin Bloch; Courtney A Crane; Rajwant Kaur; Michael Safaee; Martin J Rutkowski; Andrew T Parsa
Journal:  Clin Cancer Res       Date:  2013-04-23       Impact factor: 12.531

Review 9.  Overview of cellular immunotherapy for patients with glioblastoma.

Authors:  Elodie Vauleon; Tony Avril; Brigitte Collet; Jean Mosser; Véronique Quillien
Journal:  Clin Dev Immunol       Date:  2010-10-04

10.  GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells.

Authors:  Gaurisankar Sa; Tanya Das; Christina Moon; Cynthia M Hilston; Patricia A Rayman; Brian I Rini; Charles S Tannenbaum; James H Finke
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.